{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:44:57Z","timestamp":1793051097590,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404000"],"award-info":[{"award-number":["2023YFC3404000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371781"],"award-info":[{"award-number":["82371781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073752"],"award-info":[{"award-number":["82073752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114325","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:12:04Z","timestamp":1760501524000},"page":"114325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P1","title":["Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate"],"prefix":"10.1016","volume":"388","author":[{"given":"Guangjun","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114325_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.114325_bb0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1186\/s12885-024-12652-5","article-title":"Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2025.114325_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2025.114325_bb0020","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/acs.molpharmaceut.6b00153","article-title":"Altering antibody-drug conjugate binding to the neonatal fc receptor impacts efficacy and tolerability","volume":"13","author":"Hamblett","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114325_bb0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114325_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","article-title":"Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake","volume":"62","author":"Gorovits","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2025.114325_bb0035","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"Cruz","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.jconrel.2025.114325_bb0040","doi-asserted-by":"crossref","first-page":"649","DOI":"10.20892\/j.issn.2095-3941.2020.0704","article-title":"Strategies to enhance monoclonal antibody uptake and distribution in solid tumors","volume":"18","author":"Bordeau","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jconrel.2025.114325_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.114325_bb0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114325_bb0055","doi-asserted-by":"crossref","first-page":"W534","DOI":"10.1093\/nar\/gkaf388","article-title":"TIMER3: an enhanced resource for tumor immune analysis","volume":"53","author":"Cui","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.114325_bb0060","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.114325_bb0065","doi-asserted-by":"crossref","first-page":"25106","DOI":"10.1074\/jbc.M116.753491","article-title":"Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) x c-MET antibodies and antibody-drug conjugates","volume":"291","author":"Sellmann","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.114325_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465722","article-title":"Trends and challenges in bispecific antibody production","volume":"1744","author":"Karbyshev","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2025.114325_bb0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of Nanobodies","volume":"34","author":"Jovcevska","year":"2020","journal-title":"BioDrugs"},{"issue":"2024","key":"10.1016\/j.jconrel.2025.114325_bb0080","article-title":"Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy","volume":"5","author":"Li","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.jconrel.2025.114325_bb0085","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1021\/ac501202d","article-title":"VHH phage-based competitive real-time immuno-polymerase chain reaction for ultrasensitive detection of ochratoxin a in cereal","volume":"86","author":"Liu","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2025.114325_bb0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-974-7_13","article-title":"Humanization by CDR grafting and specificity-determining residue grafting","volume":"907","author":"Kim","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.114325_bb0095","first-page":"1391","article-title":"Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs\u2019 development","volume":"128","author":"Moretto","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114325_bb0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.jconrel.2025.114325_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103838","article-title":"Targeted therapeutic strategies for Nectin-4 in breast cancer: recent advances and future prospects","volume":"79","author":"Wang","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.jconrel.2025.114325_bb0110","first-page":"221","article-title":"Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity","volume":"7","author":"Wang","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.jconrel.2025.114325_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bjc.2017.171","article-title":"Tumour heterogeneity poses a significant challenge to cancer biomarker research","volume":"117","author":"Cyll","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114325_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2025.114325_bb0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114325_bb0130","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114325_bb0135","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/pharmaceutics15061761","article-title":"Business risk mitigation in the development process of new monoclonal antibody drug conjugates for cancer treatment","volume":"15","author":"Kiss","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.114325_bb0140","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2214-109X(24)00442-X","article-title":"Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis","volume":"13","author":"Oldfield","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2025.114325_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1449707","article-title":"Escalating costs of innovative medicines: perspective and proposals","volume":"12","author":"Vallano","year":"2024","journal-title":"Front. Public Health"},{"key":"10.1016\/j.jconrel.2025.114325_bb0150","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/cancers16152681","article-title":"Single-domain antibodies as antibody\u2013drug conjugates: from promise to practice\u2014a systematic review","volume":"16","author":"P\u00e9rez","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.114325_bb0155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2025.114325_bb0160","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.114325_bb0165","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12951-024-03008-z","article-title":"Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy","volume":"22","author":"Dewulf","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114325_bb0170","series-title":"An Overview of the Current ADC Discovery Landscape","first-page":"1","author":"Tumey","year":"2020"},{"key":"10.1016\/j.jconrel.2025.114325_bb0175","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.114325_bb0180","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114325_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.114325_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2230618","article-title":"Therapeutic index improvement of antibody-drug conjugates","volume":"15","author":"Gerber","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2025.114325_bb0195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-024-00887-w","article-title":"An explanation of why dose-corrected area under the curve for alternate administration routes can be greater than for intravenous dosing","volume":"26","author":"Wakuda","year":"2024","journal-title":"AAPS J."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:00:52Z","timestamp":1769868052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0168365925009393"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114325","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114325"}}